Conflict of Interest Disclosures: Dr de Lemos reported receiving personal fees from Amgen, Regeneron, Esperion, and NovoNordisk outside the submitted work. Dr Mues reported receiving personal fees from Amgen, Inc, where she is an employee and stockholder. Dr Bhatt reported serving on the GOULD steering committee during the conduct of the study; receiving grants from sanofi aventis, ODYSSEY, Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, The Medicines Company, Roche, Pfizer, Ischemix, Forest Laboratories, Eli Lilly, Chiesi, Ironwood, Cardax, Regeneron, Abbott, PhaseBio, Idorsia, Synaptic, Fractyl, Afimmune, and Lexicon; having nonmonetary relationships with the NDCR-ACTION Registry Steering Committee (Chair), the US Department of Veterans Affairs (Chair of the VA CART Research and Publications Committee), FlowCo, PLx Pharma, Takeda, Medscape Cardiology, Regado Biosciences, Boston VA Research Institute, Clinical Cardiology (Deputy Editor), Boston Scientific, St. Jude Medical (now Abbott), Biotronik, Merck, Svelte, NovoNordisk, Cereno Scientific, and CSI; receiving personal fees from Duke Clinical Research Institute, Mayo Clinic, Population Health Research Institute, Belvoir Publications, Slack Publications, WebMD, Elsevier, HMP Global, Harvard Clinical Research Institute (now Baim Institute for Clinical Research), Journal of the American College of Cardiology, Cleveland Clinic, Mount Sinai School of Medicine, TobeSoft, Boehringer Ingelheim, Bayer, Medtelligence/ReachMD, CSL Behring, and Ferring Pharmaceuticals; receiving personal fees and nonfinancial support from the American College of Cardiology and the Society of Cardiovascular Patient Care; and receiving nonfinancial support from the American Heart Association outside the submitted work. Dr Cannon reported receiving grants from Ad Board, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, and Pfizer; and personal fees from Aegerion, Alnylam, Amgen, Applied Therapeutics, Ascendia, Boehringer-Ingelheim, Bristol-Myers Squibb, Corvidia, HLS Therapeutics, Innovent, Janssen, Kowa, Merck, Pfizer, and Sanofi Ad boards outside the submitted work. Dr Kosiborod reported receiving grants from Astra Zeneca and Boehringer-Ingelheim and personal fees from Amarin, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, GlaxoSmithKline, Glytec, Janssen, Merck (Diabetes), Novartis, NovoNordisk, Sanofi, and Vifor Pharma outside the submitted work. No other disclosures were reported.
